Business Context and Reporting Period
This Form 8-K is a current report filed by Organovo Holdings, Inc. (not Vivosim Labs, INC.) on March 19, 2025. The registrant is a Delaware corporation with principal executive offices in San Diego, California. The filing discloses a material corporate action regarding its capital structure.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose a pending corporate event.
Material Changes
- Reverse Stock Split: On March 19, 2025, the company issued a press release announcing a pending reverse split of its common stock.
- Regulation FD Disclosure: The announcement was made pursuant to Item 7.01 (Regulation FD Disclosure) to ensure public dissemination of material non-public information.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the implications of the reverse stock split. The press release detailing the reverse split is attached as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific ratio and effective date of the pending reverse stock split in the attached press release (Exhibit 99.1).
- Confirm the ticker symbol ONVO on The Nasdaq Stock Market LLC for trading updates.
- Review subsequent filings for the official implementation of the reverse split and any impact on share count.
- Note that the registrant name in the metadata request ("Vivosim Labs, INC.") does not match the filing registrant ("Organovo Holdings, Inc."); verify the correct entity for investment purposes.